TY - JOUR T1 - High failure rate of ChAdOx1 in healthcare workers during Delta variant surge: A case for continued use of masks post-vaccination JF - medRxiv DO - 10.1101/2021.02.28.21252621 SP - 2021.02.28.21252621 AU - Rajat Ujjainiya AU - Akansha Tyagi AU - Viren Sardana AU - Salwa Naushin AU - Nitin Bhatheja AU - Kartik Kumar AU - Joydeb Barman AU - Satyartha Prakash AU - Rintu Kutum AU - Akash K Bhaskar AU - Prateek Singh AU - Kumardeep Chaudhary AU - Menka Loomba AU - Yukti Khanna AU - Chestha Walecha AU - Rizwan Ahmed AU - Ashutosh Yadav AU - Archana Bajaj AU - Gaurav Malik AU - Sahar Qureshi AU - Swati Waghdhare AU - Samreen Siddiqui AU - Kamal Krishan Trehan AU - Manju Mani AU - Rajiv Dang AU - Poonam Das AU - Pankaj Dougall AU - Monica Mahajan AU - Sudipta Sonar AU - Kamini Jakhar AU - Reema Kumar AU - Mahima Tiwari AU - Shailendra Mani AU - Sankar Bhattacharyya AU - Sandeep Budhiraja AU - Anurag Agrawal AU - Debasis Dash AU - Sujeet Jha AU - Shantanu Sengupta Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/02/2021.02.28.21252621.abstract N2 - Immunization is expected to confer protection against infection and severe disease for vaccinees, while reducing risks to unimmunized populations by inhibiting transmission. Here, based on serial serological studies, we show that during a severe SARS-CoV2 Delta-variant outbreak in Delhi, 25.3% (95% CI 16.9 - 35.2) of previously uninfected, ChAdOx1-nCoV19 double vaccinated, healthcare-workers (HCW) were infected within a period of less than two months, based on serology. Induction of anti-spike response was similar between groups with breakthrough infection (541 U/ml, IQR 374) or not (342 U/ml, IQR 497), as was induction of neutralization activity to wildtype. Most infections were unrecognized. The Delta-variant thus causes frequent unrecognized breakthrough infections in adequately immunized subjects, reducing any herd-effect of immunity, and requiring reinstatement of preventive measures such as masking.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSSG would like to acknowledge CSIR grant MLP 2007 for this work. The sponsor of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institute Ethics Committee (Max healthcare Committee), New Delhi with separate approval for all sites and CSIR-IGIB, New Delhi IHECAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for de-identified data may be send to the corresponding authors stating end usage. Data will be shared on request basis. ER -